Deciphera Pharmaceuticals Inc (NASDAQ:DCPH) Director Sells $917,325.00 in Stock

Share on StockTwits

Deciphera Pharmaceuticals Inc (NASDAQ:DCPH) Director Michael Douglas Taylor sold 22,500 shares of the firm’s stock in a transaction dated Tuesday, August 13th. The stock was sold at an average price of $40.77, for a total value of $917,325.00. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link.

NASDAQ:DCPH opened at $36.30 on Friday. The company has a debt-to-equity ratio of 0.01, a quick ratio of 7.26 and a current ratio of 7.26. The company has a market cap of $762.39 million, a PE ratio of -12.87 and a beta of 2.34. Deciphera Pharmaceuticals Inc has a 52-week low of $18.55 and a 52-week high of $42.99. The stock has a 50-day simple moving average of $23.11 and a 200 day simple moving average of $24.33.

Deciphera Pharmaceuticals (NASDAQ:DCPH) last posted its quarterly earnings data on Friday, August 2nd. The company reported ($0.56) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($1.12) by $0.56. The firm had revenue of $25.00 million for the quarter, compared to the consensus estimate of $20.00 million. On average, research analysts predict that Deciphera Pharmaceuticals Inc will post -4.29 earnings per share for the current fiscal year.

DCPH has been the topic of a number of research analyst reports. BidaskClub raised Deciphera Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Friday. Deutsche Bank initiated coverage on Deciphera Pharmaceuticals in a research report on Thursday, July 18th. They set a “buy” rating and a $42.00 price target on the stock. Zacks Investment Research raised Deciphera Pharmaceuticals from a “sell” rating to a “hold” rating and set a $26.00 price target on the stock in a research report on Monday, August 5th. ValuEngine lowered Deciphera Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Tuesday. Finally, SunTrust Banks raised their price target on Deciphera Pharmaceuticals to $60.00 and gave the stock a “buy” rating in a research report on Wednesday. Four research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. Deciphera Pharmaceuticals presently has a consensus rating of “Buy” and an average price target of $47.90.

Several large investors have recently bought and sold shares of the stock. BlackRock Inc. grew its holdings in shares of Deciphera Pharmaceuticals by 25.6% during the second quarter. BlackRock Inc. now owns 1,531,844 shares of the company’s stock worth $34,543,000 after buying an additional 311,870 shares in the last quarter. Vanguard Group Inc. grew its holdings in shares of Deciphera Pharmaceuticals by 2.6% during the second quarter. Vanguard Group Inc. now owns 792,654 shares of the company’s stock worth $17,874,000 after buying an additional 20,252 shares in the last quarter. Janus Henderson Group PLC grew its holdings in shares of Deciphera Pharmaceuticals by 2.1% during the second quarter. Janus Henderson Group PLC now owns 675,707 shares of the company’s stock worth $15,237,000 after buying an additional 14,028 shares in the last quarter. Norges Bank bought a new position in shares of Deciphera Pharmaceuticals during the fourth quarter worth about $6,974,000. Finally, Eversept Partners LP grew its holdings in shares of Deciphera Pharmaceuticals by 21.9% during the second quarter. Eversept Partners LP now owns 305,233 shares of the company’s stock worth $6,883,000 after buying an additional 54,801 shares in the last quarter. Institutional investors and hedge funds own 59.10% of the company’s stock.

Deciphera Pharmaceuticals Company Profile

Deciphera Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response of various cancer therapies. The company's lead drug candidate is DCC-2618, which is in Phase III trial for the treatment of gastrointestinal stromal tumors; and that is in Phase I trial for treating advanced systemic mastocytosis, gliomas, melanoma, NSCLC/germ cell/penile, and soft tissue sarcomas.

Further Reading: Growth Stocks

Insider Buying and Selling by Quarter for Deciphera Pharmaceuticals (NASDAQ:DCPH)

Receive News & Ratings for Deciphera Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Deciphera Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Lundin Mining Co.  Insider Nemesia S.a.r.l.  Acquires 150,000 Shares
Lundin Mining Co. Insider Nemesia S.a.r.l. Acquires 150,000 Shares
Brian B. Hansen Sells 15,000 Shares of Tandem Diabetes Care Inc  Stock
Brian B. Hansen Sells 15,000 Shares of Tandem Diabetes Care Inc Stock
Osisko gold royalties Ltd  Director Sells C$897,627.00 in Stock
Osisko gold royalties Ltd Director Sells C$897,627.00 in Stock
Deciphera Pharmaceuticals Inc  Director Sells $917,325.00 in Stock
Deciphera Pharmaceuticals Inc Director Sells $917,325.00 in Stock
Boston Advisors LLC Decreases Stock Holdings in Textron Inc.
Boston Advisors LLC Decreases Stock Holdings in Textron Inc.
Sumedh S. Thakar Sells 6,980 Shares of Qualys Inc  Stock
Sumedh S. Thakar Sells 6,980 Shares of Qualys Inc Stock


© 2006-2019 Ticker Report